Mankind’s journey began in 1995 with only 53 Medical Representatives and Managers. Today, Mankind is one of the top 5 leading pharmaceutical companies in India with a dedicated field force of over 1968 professionals. Mankind Pharma achieved a turnover of Rs. 17250 million for the fiscal year 2019-20 with a growth of 20%. Mankind Pharma contributed 30% in Mankind Group of Company’s sales which was Rs. 56760 million in 2019-20 .
Mankind Pharma focuses on a variety of therapeutic segments such as Cardiovascular, Antibiotics, Gastro-intestinal, Anti-allergic, Anti-fungal, Nutritional, NSAIDs, Ortho and Gynaecological. Every day 75 Lacs Indians consume Mankind's cardiac care products. Mankind has launched many innovative and successful products such as Placida, Zolahart, Overzyme in the Indian market and economical brands like Nurokind, Moxikind, Telmikind, Cefakind, and Rabekind.
The total net worth of Mankind Pharma’s products are as follows: Telmikind (Rs. 2644 million), Moxikind-CV (Rs. 2175 million), Amlokind (Rs. 1903 million), Nurokind (Rs. 1322 million), Cefakind (Rs. 950 million) and Zenflox (Rs. 781 million). Mankind Pharma gives equal emphasis to quality and compliance. All our manufacturing processes adhere to GMP guidelines to ensure excellent quality standards. Technology and Research and Development play a vital role in creating quality health care products. Mankind manufactures a wide range of dosage forms including oral solids, oral liquids, soft gelatine capsules and injectables. It also creates products that require specialized conditions such as controlled-release pharmaceutical products, controlled humidity and temperature conditions etc.
Mankind Pharma’s mission is to improve the quality of life, to continue to be recognized as a reliable provider of health care products and nurture innovation that leads to collective excellence.